TiGenix NV (Euronext Brussels: TIG) is an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic, or donor-derived, expanded stem cells. Two products from the adipose-derived stem cell technology platform are currently in clinical development. - Cx601 is in Phase III for the treatment of complex perianal fistulas in Crohn’s disease patients. On July 4, 2016, we entered into a licensing agreement with Takeda, a large pharmaceutical company active in gastroenterology, under which Takeda acquired the exclusive right to commercialize Cx601 for complex perianal fistulas outside the United States. - Cx611 has completed a Phase I sepsis challenge trial and a Phase I/II trial in rheumatoid arthritis.  Effective July 31, 2015, TiGenix acquired Coretherapix, whose lead cellular product, AlloCSC-01, is currently in a Phase II clinical trial in acute myocardial infarction (AMI). In addition, the second product candidate from the cardiac stem cell-based platform acquired from Coretherapix, AlloCSC-02, is being developed in a chronic indication. TiGenix is based in Leuven, Belgium, and has operations in Madrid, Spain.
Leuven, BE
Size (employees)
65 (est)
TiGenix was founded in 2000 and is headquartered in Leuven, BE

Key People/Management at TiGenix

Eduardo Bravo

Eduardo Bravo

Managing Director and Chief Executive Officer
Claudia D’Augusta

Claudia D’Augusta

Chief Financial Officer
Marie Richard

Marie Richard

Chief Medical Officer
Wilfried Dalemans

Wilfried Dalemans

Chief Technical Officer
Mary Diez

Mary Diez

Vice President Medical Affairs and New Product Commercialisation
Maria Pascual

Maria Pascual

Vice President Regulatory Affaris and Corporate Quality
Susana Rojo

Susana Rojo

Director of Human Resources

TiGenix Office Locations

TiGenix has an office in Leuven
Leuven, BE (HQ)
12 Romeinse straat

TiGenix Financials and Metrics

TiGenix Financials


Market capitalization (31-Oct-2017)

254.8 m

Closing share price (31-Oct-2017)

TiGenix's current market capitalization is €254.8 m.
Show all financial metrics

TiGenix Market Value History

TiGenix's Web-traffic and Trends

TiGenix Online and Social Media Presence

TiGenix Company Life and Culture

You may also be interested in